Serum β2 microglobulin (β2MG) level is a potential predictor for encapsulating peritoneal sclerosis (EPS) in peritoneal dialysis patients

Clinical Nephrology

Volumn 69, Issue 2, 2008, Pages 121-126

  Yokoyama, Keitaro ^a   Yoshida, H ^a   Matsuo, N ^a   Maruyama, Y ^a   Kawamura, Y ^a   Yamamoto, R ^a   Hanaoka, K ^a   Ikeda, M ^a   Yamamoto, H ^a   Nakayama, M ^b   Kawaguchi, Y ^a   Hosoya, T ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Encapsulating peritoneal sclerosis; Peritoneal dialysis; 2 microglobulin

Indexed keywords

BETA 2 MICROGLOBULIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; NITROGEN; UREA; BIOLOGICAL MARKER;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENCAPSULATING PERITONEAL SCLEROSIS; FEMALE; HUMAN; MALE; MULTIPLE REGRESSION; NORMAL VALUE; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SCLEROSIS; SENSITIVITY AND SPECIFICITY; UREA NITROGEN BLOOD LEVEL; BLOOD; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; FOLLOW UP; MIDDLE AGED; PATHOLOGY; PERITONEUM; PROGNOSIS; RETROSPECTIVE STUDY; RISK; ROC CURVE; TIME;

BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; CONFIDENCE INTERVALS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; ODDS RATIO; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PERITONEUM; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; SCLEROSIS; TIME FACTORS;

EID: 38949140466     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp69121     Document Type: Article

References (18)

1. 2M Removal Membrane. Nephrol Dial Transplant. 1995; 10 Suppl 7: 7-15.
2. 2-microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol. 2006; 17: 546-555.
3. Chin AI, Yeun JY. Encapsulating peritoneal sclerosis: an unpredictable and devastating complication of peritoneal dialysis. Am J Kidney Dis. 2006; 47: 697-712.
4. Evenepoel P, Bammens B, Verbeke K, Vanrentergem Y. Superior dialytic clearance of beta(2)-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis. Kidney Int. 2006; 70: 794-799.
5. Kawaguchi Y, Kawanishi H, Mujais S, Topley N, Oreopoulos DG. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int. 2000; 20 Suppl 4: 43-55.
6. Kawanishi H, Kawaguchi Y, Fukui H, Hara S, Imada A, Kuho H, Kin M, Nakamoto M, Ohira S, Shoji T. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis. 2004; 44: 729-737.
7. Krediet RT. Evaluation of peritoneal membrane integrity. J Nephrol. 1997; 10: 238-244.
8. 2-microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. J Clin Invest. 1996; 98: 1088-1094.
9. 2-microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. Kidney Int. 1997; 51: 182-186.
10. Nakayama M. The plasma leak-to-response hypothesis: a working hypothesis on the pathogenesis of encapsulating peritoneal sclerosis after long-term peritoneal dialysis treatment. Perit Dial Int. 2005; Suppl 4: 71-76.
11. Numata M, Nakayama M, Hosoya T, Hoff CM, Holmes CJ, Schalling M, Nordfors L, Lindholm B. Possible pathologic involvement of receptor for advanced glycation end products (RAGE) for development of encapsulating peritoneal sclerosis in Japanese CAPD patients. Clin Nephrol. 2004; 62: 455-460.
12. Sherif AM, Nakayama M, Masuyama Y, Yoshida H, Yamamoto H, Yokoyama K, Kawakansi M. Quantitative assessment of the peritoneal vessel density and vasculopathy in CAPD patients. Nephrol Dial Transplant. 2006; 21: 1675-1681.
13. Summers AM, Clancy MJ, Syed F, Harwood N, Brenchley PE, Augustine T, Riad H, Hutchison AJ, Taylor P, Pearson R, Gokal R. Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. Kidney Int. 2005; 68: 2381-2388.
14. Szeto CC, Poon P, Szeto CY, Wong TY, Lai KB, Li PK. Plasminogen activator inhibitor-1 4G/5G genetic polymorphism does not affect peritoneal transport characteristic. Am J Kidney Dis. 2002; 39: 1061-1067.
15. Szeto CC, Wong TY, Lai KB, Lam CW, Lai KN, Li PK. Dialysate hyaluronan concentration predicts survival but not peritoneal sclerosis in continuous ambulatoty peritoneal dialysis. Am J Kidney Dis. 2000; 36: 609-614.
16. 2-microglobulin. Amyloid. 2001; 8: 30-40.
17. Yamamoto R, Otsuka Y, Nakayama M, Maruyama Y, Katoh N, Ikeda M, Yamamoto H, Yokoyama K, Kawaguchi Y, Matsushima M. Risk factors for encapsulating peritoneal sclerosis in patients who have experienced peritoneal dialysis treatment. Clin Exp Nephrol. 2005; 9: 148-152.
18. 2-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis. Kidney Int. 2007; 71: 467.